Abstract 1806P
Background
Extensive disease small cell lung cancer (ED-SCLC) accounts for more than 70% of new diagnoses of SCLC with a 5-year survival of 2.8%. A limited portion of ED-SCLC achieved a long term survival but their clinical and biological characteristics are largely unknown. Here we reported baseline clinical characteristics and treatment sequences of a large cohort of long survivors ED-SCLC and we compared them to patients showing a poor outcomes.
Methods
The Epidemio-Strategy and Medical Economics (ESME) lung cancer data platform is a multicenter real-life database using a retrospective data collection process. We selected ED-SCLC patients diagnosed between 2014 and 2021 and having a minimum follow-up of 3 years. Long survivors were defined as having an overall survival (OS) ≥ 24 months. Statistical comparisons were performed by Pearson’s Chi-square, and univariate logistic regression.
Results
We identified 3949 ED-SCLC and 437 long survivors representing 11% of the study population. mOS was 36 months (95%CI 34 to 39) in long survivors and 9 months (95%CI 8.9 to 9.4) in other patients. Compared to other patients, long survivors were enriched in women (45% in long survivors vs 34% in other patients, Odds-Ratio [OR]: 1.60 [1.31 -1.96], p < 0.001), younger patients (63 [IQR: 58,70] vs 66 [IQR: 59,72] years old, OR: 0.97 [0.96-0.98], p < 0.001) and patients with ECOG PS 0-1 at diagnosis (85% vs 58%, OR: 4.05, p
Conclusions
Long survivors represents a small proportion of ED-SCLC characterized by a more indolent disease at diagnosis. Biological characteristics of these patients should be investigated in order to inform clinical research for new therapeutic strategies.
Clinical trial identification
NCT03848052.
Editorial acknowledgement
Legal entity responsible for the study
Unicancer / Institut Curie.
Funding
The ESME LC database receives financial support from industrial partners. Unicancer manages ESME databases independently (i.e. data collection, analysis and publication) and is the sole data controller for data processing.
Disclosure
E. Gobbini: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Institutional, Research Grant: BMS, AstraZeneca; Non-Financial Interests, Principal Investigator: Janssen; Other, Spouse of AstraZeneca employee: AstraZeneca. C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. D. Debieuvre: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Janssen, Sanofi-Winthrop, Amgen, Roche; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Coordinating PI: Pfizer; Financial Interests, Institutional, Funding: Roche, AstraZeneca, Janssen, MSD, Pfizer, BMS, Lilly, Boehringer Ingelheim, GSK, Chugaï, Chiesi, Takeda, Bayer, Sanofi-Winthrop, Amgen, AbbVie. X. Quantin: Financial Interests, Institutional, Invited Speaker: SANOFI; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Other, Educational support: AstraZeneca. C. Audigier Valette: Financial Interests, Personal, Advisory Board: Roche, BMS, MSD, AstraZeneca, Sanofi, Janssen, Amgen, Biodena care; Financial Interests, Personal, Invited Speaker: Pfizer; Non-Financial Interests, Advisory Role, Scientific committee: IFCT; Non-Financial Interests, Principal Investigator: GFPC; Non-Financial Interests, Member of Board of Directors, Editorial CommitteeLettre du Cancérologue Actualités en Oncologie Thoracique: Edimark; Non-Financial Interests, Member of Board of Directors, President: 3C VAR OUEST. G. Justeau: Non-Financial Interests, Advisory Role: BMS. A. Madroszyk Flandin: Financial Interests, Personal, Advisory Board, board 24/05/23: Janssen; Financial Interests, Personal, Advisory Board, 10/2021: AstraZeneca. O. Bylicki: Financial Interests, Personal, Advisory Board, Expert Board: BMS, Roche, Takeda; Financial Interests, Personal, Other, Travel congress: MSD; Financial Interests, Personal, Advisory Board, expert board: AstraZeneca, janssen; Financial Interests, Personal, Advisory Board, Board: MSD; Financial Interests, Personal, Other, Travel Congress: AstraZeneca. L. Bosquet: Financial Interests, Institutional, Full or part-time Employment, In charge of scientific projects at Unicancer, Health Data and Partnership Department: Unicancer. M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen, AstraZeneca, AbbVie, Anheart Therapeutics, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Personal, Advisory Board, Advisory board: Novocure; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Steering Committee Member: Roche, Sophiagenetics, PharmaMar, Anheart Therapeutics; Financial Interests, Personal, Other, DMSB: Roche; Financial Interests, Institutional, Local PI: AstraZeneca, Amgen, Roche, AbbVie, Apollomics, Anheart Therapeutics, Innate Pharma, Boehringer Ingelheim, Arrivent Biopharma, Daiichi Sankyo, Bayer; Financial Interests, Steering Committee Member: Lilly. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer Ingelheim Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Family member is an employee: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07
1800P - Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
Presenter: Carminia Della Corte
Session: Poster session 07
1801P - Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Presenter: Kenneth O'Byrne
Session: Poster session 07